ClinicalTrials.gg
RecruitingNCT07569952Updated May 6, 2026

Sphenopalatine Ganglion Block as Adjuvant to General Anesthesia Regarding the Quality of Surgical Field in Trans-Sphenoidal Endoscopic Hypophysectomy

An interventional study of Sphenopalatine ganglion block using bupivacaine + dexamethasone and General anesthesia in Sphenopalatine Ganglion Block, General Anesthesia and Quality of Surgical Field, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 21 Months to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
21 Months to 60 Years
Sex
All
01

Study summary

This study aims to evaluate the efficacy of ultrasound guided sphenopalatine ganglion block (SPGB) through the suprazygomatic approach in optimizing the quality of surgical field as well as its effect on postoperative pain relief in patients undergoing transsphenoidal pituitary surgeries under general anesthesia.

Read the detailed description

The main surgical treatment for pituitary adenomas is endoscopic trans-sphenoidal hypophysectomy.

Among the many regional blocks used is the sphenopalatine ganglion block (SPGB). It is one of the parasympathetic ganglia in the head, located in the pterygopalatine fossa, posterior to the middle nasal turbinate, 1-5 mm deep to the mucosa, anterior to the pterygoid canal and lateral to the sphenopalatine foramen.

This superficial location makes it easy to block the ganglion transnasally by topical anesthesia or by injection through many approaches including transnasal, intraoral, infrazygomatic and suprazygomatic approaches.

02

Conditions studied

  • Sphenopalatine Ganglion Block
  • General Anesthesia
  • Quality of Surgical Field
  • Trans-Sphenoidal Endoscopic Hypophysectomy

Browse trials for

03

In context

Ganglion Cysts

42 studies on the registry are indexed under Ganglion Cysts; 7 are open to participants now.

This study's planned enrollment of 70 is above the median of 62 across 31 interventional studies indexed under Ganglion Cysts.

Browse Ganglion Cysts studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Months to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 21 and 60 years.
  • (ASA) Physical Status I or II.
  • Undergoing elective endoscopic trans-nasal resection of pituitary adenoma.

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal
  • ASA Physical Status III or IV patients
  • Patients receiving drugs influencing blood coagulation
  • Allergy to any of the drugs utilized in this study
  • History of chronic pain therapy
  • Inadvertent intra-operative vascular injury
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group A

    Patients will receive sphenopalatine ganglion block (SPGB) using 4 mL of 0.25% bupivacaine combined with 1 mL of dexamethasone .

    Drug: Sphenopalatine ganglion block using bupivacaine + dexamethasone

  • Active comparator
    Group B

    Patients will receive general anesthesia alone.

    Other: General anesthesia

Interventions

  • DrugSphenopalatine ganglion block using bupivacaine + dexamethasone

    Patients will receive sphenopalatine ganglion block (SPGB) using 4 mL of 0.25% bupivacaine combined with 1 mL of dexamethasone.

  • OtherGeneral anesthesia

    Patients will receive general anesthesia alone.

06

What researchers measure

Primary outcomes

  1. Quality of surgical field visibility

    Quality of surgical field visibility will be measured at the beginning of surgery and at 30 mins interval through a pre-defined average category scale (ACS) (from 0 to 5). The ideal category scale values for surgical conditions were pre-determined to be ≤3. 0=No bleeding 1. Slight bleeding - no suctioning of blood required 2. Slight bleeding - occasional suctioning required. Surgical field not threatened 3. Slight bleeding - frequent suctioning required. Bleeding threatens surgical field a few seconds after suction is removed 4. Moderate bleeding - frequent suctioning required. Bleeding threatens surgical field directly after suction is removed 5. Severe bleeding - constant suctioning required. Bleeding appears faster than can be removed by suction. Surgical field severely threatened and surgery not possible

    Time frame: Intraoperatively

Secondary outcomes

  1. Intraoperative fentanyl consumption

    The hemodynamic objective of the anesthetic plan is to maintain mean arterial pressure values between 60 mmHg and 65 mmHg to produce an optimal surgical field, this will be done by injection of increments of fentanyl (0.5 μg/kg) up to total dose of 3 μg/kg

    Time frame: Intraoperatively

  2. Total dose of propranolol

    In case of reflex persistent increase in heart rate (HR) \>100 beats/min, i.v. 0.2 mg increments of propranolol will be given to maintain HR 60-70 beats/min.

    Time frame: Intraoperatively

  3. Total dose of nitroglycerine

    In case of reduction of mean arterial pressure (MAP), nitroglycerine infusion will be done through adjustment from 0.5 to 10 μg/kg/ min according to patient response.

    Time frame: Intraoperatively

  4. Amount of intraoperative blood loss

    Amount of intraoperative blood loss (by measuring the volume of blood in suction reservoir minus the normal saline used to wash the surgical field)

    Time frame: Intraoperatively

  5. Degree of pain

    Each patient will be instructed about postoperative pain assessment with visual analog scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be measured immediately after the operation, then at 2, 12, and 24hrs.

    Time frame: 24 hours postoperatively

  6. Time of 1st analgesia requirement

    Postoperative analgesia is performed with administration of paracetamol/acetaminophen (1 g three times a day) and visual analog scale (VAS) ≥4 will be managed by IV dose of 25mg pethidine.

    Time frame: 24 hours postoperatively

  7. Total meperidine consumption

    Total postoperative meperidine consumption will be recorded.

    Time frame: 24 hours postoperatively

  8. Incidence of postoperative side effects

    Incidence of postoperative side effects such as postoperative nausea and vomiting (PONV), headache, visual disturbances, agitation or somnolence will be recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Cairo University
    Cairo, 12613, Egypt
    Recruiting
    • Nada A Fathy, MSc · Contactnashrsf@gmail.com · 00201094049394
    • Khaled Alshafei, MD · Sub investigator
    • Safinaz H Osman, MD · Sub investigator
    • Mohamed Farid, MD · Sub investigator
    • Maged Gamal, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 16 interventional studies with no phase under Ganglion Cysts, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 6, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569952
Lead sponsor
Cairo University
Responsible party
Nada Ashraf Mohamed Fathy (Assistant Lecturer of Anesthesiology, Surgical ICU and Pain Management, Cairo University, Cairo, Egypt., Cairo University) — Principal investigator
First posted
May 6, 2026
Start date
Jun 1, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Nada A Fathy, MSc
Contact
nashrsf@gmail.com
00201094049394

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion